12K+ US Cases/Yr, <2-Yr Survival: Biotech's Glioblastoma Challenge
Annual glioblastoma diagnoses exceed 12,000 with a grim sub-two-year life expectancy, spotlighting a high-priority target for biotech investment and therapeutic innovation. Dr. Annick Desjardins' awareness messaging underscores the rapid proliferation and clinical chaos that keep this disease among oncology’s toughest nuts to crack.
Source: nbcphiladelphia.com · nbcdfw.com